Therapeutic | Tocilizumab |
Target | IL6R/CD126 |
Heavy Chain | QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIK |
100% seqID Fv Structure | 8j6f [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 8j6f [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (Feb '25) | Approved |
Estimated Status (Feb '25) | Active |
Recorded Developmental Technology | |
INN Year Proposed | 2004 |
INN Year Recommended | 2004 |
Companies Involved | Assistance Publique Hopitaux de Paris, Charite - Universitatsmedizin Berlin, Chugai Pharmaceutical, Hospital for Special Surgery, JW Pharmaceutical, Roche, University Hospital Inselspital, University Hospital, Osaka University Tubingen, University of Bern, University of Pittsburgh |
Conditions Approved | Drug hypersensitivity, Giant cell arteritis, Giant lymph node hyperplasia, Juvenile rheumatoid arthritis, Rheumatoid arthritis, Vasculitis |
Conditions Active | Adult-onset Still's disease, Osteoarthritis, Systemic scleroderma, Amyotrophic lateral sclerosis, Dermatomyositis, Familial Mediterranean fever, Polymyalgia rheumatica, Polymyositis, Pulmonary arterial hypertension, Schnitzler syndrome, Urogenital cancer |
Conditions Discontinued | Chronic lymphocytic leukaemia, Ankylosing spondylitis, Crohn's disease, Multiple myeloma, Pancreatic cancer, Systemic lupus erythematosus |
Notes | Biosimilars available |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]